Evidence map›Paper›PMID 38886578›Full record

ArticleThe EMBO journal2024

Egr2 to the rescue: nanoparticles revitalize natural killer cells in the fight against cancer.

Aline Pfefferle, Santosh Phuyal, Herman Netskar, Karl-Johan Malmberg

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The EMBO journal, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Aline PfefferleCenter for Infectious Medicine, Department of Medicine Huddinge, Karolinska Institutet, Stockholm, Sweden.ORCID http://orcid.org/0000-0002-8181-537X
Santosh PhuyalPrecision Immunotherapy Alliance, University of Oslo, Oslo, Norway.ORCID http://orcid.org/0000-0002-1922-2098
Herman NetskarPrecision Immunotherapy Alliance, University of Oslo, Oslo, Norway.
Karl-Johan MalmbergCenter for Infectious Medicine, Department of Medicine Huddinge, Karolinska Institutet, Stockholm, Sweden. k.j.malmberg@medisin.uio.no.ORCID http://orcid.org/0000-0002-8718-9373

Funding

Therapeutic Potential of Adaptive NK Cells in Cancer and TransplantationP01CA111412 · NCI · UNIVERSITY OF MINNESOTA TWIN CITIES · PI MILLER, JEFFREY S. · 2005 to 2025
$38.2M
Kreftforeningen (NCS) 223310NCI NIH HHS P01 CA111412Norges Forskningsråd (Forskningsrådet) 237579Norges Forskningsråd (Forskningsrådet) 275469Norges Forskningsråd (Forskningsrådet) 332727
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Early Growth Response Protein 2Killer Cells, NaturalNanoparticlesNeoplasmsAnimalsHumansEarly Growth Response Protein 2

Identifiers

PMID38886578
PMCPMC11217444

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.